Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression
Completed · Phase 3
Conditions studied: Major Depression
In brief
Objective of this 16-week, open-label study is to assess the safety and tolerability of once daily application of three doses of STS during continuous dosing in the treatment of elderly subjects with major depression. Subjects will have study visits (clinic visits) at beginning of study (baseline) and study weeks 1, 3, 5, 8, 12, and 16.
Key facts
- Study ID
- NCT00285766
- Run by
- Somerset Pharmaceuticals
- People needed
- 300
- Starts
- 2002-08-01
- Expected to finish
- 2005-07-01
- Last updated by the study team
- 2008-04-22
Who can join
Age: 65 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mohammed Bari, M.D. — Chula Vista, California, United States
- Charles Meredith, M.D. — San Diego, California, United States
- Daniel Zimbroff, M.D. — Upland, California, United States
- Kathleen Toups, M.D. — Walnut Creek, California, United States
- Abbey Strauss, M.D. — Boynton Beach, Florida, United States
- Barry Baumel, M.D. — Miami Beach, Florida, United States
- Margarita Nunez, M.D. — St. Petersburg, Florida, United States
- Mildred Farmer, M.D. — St. Petersburg, Florida, United States
- Larry Eisner, M.D. — Tamarack, Florida, United States
- Andrew Cutler, M.D. — Winter Park, Florida, United States
- Robert Riesenberg, M.D. — Atlanta, Georgia, United States
- James Hartford, M.D. — Florence, Kentucky, United States
- Mitchel Kling, M.D. — Baltimore, Maryland, United States
- Louise Beckett, M.D. — Oklahoma City, Oklahoma, United States
- Penny Barnhart, M.D. — Wichita Falls, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.